The estimated Net Worth of Jay S. Duker is at least $407 mil dollars as of 10 July 2024. Dr Duker owns over 16,666 units of EyePoint Pharmaceuticals Inc stock worth over $378,827 and over the last 8 years he sold EYPT stock worth over $0. In addition, he makes $28,228 as Chief Operating Officer at EyePoint Pharmaceuticals Inc.
Sign up
Dr D EYPT stock SEC Form 4 insiders trading
Dr has made over 10 trades of the EyePoint Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 16,666 units of EYPT stock worth $136,995 on 10 July 2024.
The largest trade he's ever made was exercising 20,793 units of EyePoint Pharmaceuticals Inc stock on 5 January 2024 worth over $170,918. On average, Dr trades about 4,337 units every 76 days since 2016. As of 10 July 2024 he still owns at least 46,086 units of EyePoint Pharmaceuticals Inc stock.
You can see the complete history of Dr Duker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Jay S. Duker M.D. biography
Dr. Jay S. Duker M.D. is the Chief Operating Officer at EyePoint Pharmaceuticals Inc.
What is the salary of Dr D?
As the Chief Operating Officer of EyePoint Pharmaceuticals Inc, the total compensation of Dr D at EyePoint Pharmaceuticals Inc is $28,228. There are 7 executives at EyePoint Pharmaceuticals Inc getting paid more, with Nancy Lurker having the highest compensation of $2,079,780.
How old is Dr D?
Dr D is 62, he's been the Chief Operating Officer of EyePoint Pharmaceuticals Inc since . There are 7 older and 9 younger executives at EyePoint Pharmaceuticals Inc. The oldest executive at EyePoint Pharmaceuticals Inc is Goran Ando, 71, who is the Independent Chairman of the Board.
What's Dr D's mailing address?
Jay's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.
Insiders trading at EyePoint Pharmaceuticals Inc
Over the last 7 years, insiders at EyePoint Pharmaceuticals Inc have traded over $67,100,515 worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth $111,404,456 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Asset Management, Lp Chen B... y Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $1,746,068. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth $39,750.
What does EyePoint Pharmaceuticals Inc do?
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
What does EyePoint Pharmaceuticals Inc's logo look like?
Complete history of Dr Duker stock trades at EyePoint Pharmaceuticals Inc y Sesen Bio
EyePoint Pharmaceuticals Inc executives and stock owners
EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Nancy Lurker,
President, Chief Executive Officer, Director -
Nancy S. Lurker,
Pres, CEO & Director -
Dario Paggiarino,
Senior Vice President, Chief Medical Officer -
George Elston,
Chief Financial Officer and Head of Corporate Development -
Dr. Dario A. Paggiarino,
Sr. VP & Chief Medical Officer -
George O. Elston,
CFO & Head of Corp. Devel. -
David Scott Jones,
Sr. VP & Chief Commercial Officer -
Dr. Jay S. Duker M.D.,
Chief Operating Officer -
Joseph Rayne,
IR Contact Officer -
Kristine Peterson,
Independent Director -
David Mazzo,
Independent Director -
John Landis,
Independent Director -
David Guyer,
Independent Director -
Douglas Godshall,
Independent Director -
Ronald Eastman,
Independent Director -
Wendy DiCicco,
Director -
Jay Duker,
Chief Strategic Scientific Officer -
Said Saim,
Chief Technology Officer -
Scott Jones,
Senior Vice President, Chief Commercial Officer -
Ron Honig,
Senior Vice President, General Counsel, Secretary -
Goran Ando,
Independent Chairman of the Board -
Dr. Anna Kluczewska,
CEO of AION Diagnostics Ltd, Pres of AION Diagnostics Ltd and Director of AION Diagnostics Ltd -
Dr. John Weet,
Sr. VP of Regulatory -
Jennifer Leonard,
Sr. VP of HR & IT -
Ron I. Honig Esq.,
Sr. VP, Gen. Counsel & Company Sec. -
Said Saim,
Chief Technology Officer -
Karen L. Zaderej,
-
Leonard S Ross,
See Remarks -
Asset Management, Lp Chen B...,
-
Anthony P Adamis,
-
Michael Craig Pine,
Chief Corp Dev.&Strat. Officer -
Michael W Rogers,
-
Healthcare Partners, L.P.Ew...,
-
David Price,
CFO -
James J Barry,
Director -
Leonard M Blum,
See Remarks -
Ramiro Ribeiro,
Chief Medical Officer -
Ye Liu,
-
Stuart Duty,
-
Fred Hassan,